-
Nov 1, 2022, 10:05 AM
by
Full story
-
Nov 1, 2022, 10:04 AM
by
Full story
-
Nov 1, 2022, 01:00 AM
by
User Not Found
Bio-IT World | It’s been a big month for sequencing news. Last week, Oxford Nanopore announced the PromethION 2 (“P2”) Solo sequencer and a new collaboration with 10X Genomics to enable a streamlined workflow for sequencing full-length transcripts in single reads.
Full story
-
Oct 31, 2022, 17:33 PM
by
Drug safety and pharmacovigilance (DSPV) teams that license access to the PubHive Navigator platform can now access the newest MedDRA version when performing signal evaluation and reporting activities
Full story
-
Oct 31, 2022, 17:33 PM
by
Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation (TSE: 4543) and a leading manufacturer of injection, primary container, and infusion therapy devices, has today announced it will expand its contract development and manufacturing services for parenteral drugs to global customers.
Full story
-
Oct 31, 2022, 17:32 PM
by
Full story
-
Oct 31, 2022, 17:31 PM
by
Full story
-
Oct 28, 2022, 09:37 AM
by
Birmingham Biotech LTD, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, today announces that NoriZite™ Nasal Spray, an easy-to-use nasal device designed to block and trap inhaled virus particles, is now available to buy in the UK.
Full story
-
Oct 28, 2022, 09:36 AM
by
Samsung Biologics reports third quarter 2022 financial results
Full story
-
Oct 28, 2022, 09:34 AM
by
Full story
-
Oct 28, 2022, 09:33 AM
by
Full story
-
Oct 27, 2022, 10:12 AM
by
Full story
-
Oct 27, 2022, 10:11 AM
by
Full story
-
Oct 27, 2022, 10:09 AM
by
Contact information
Eric Blair, Chief Commercial Officer
Eric.Blair@AndelynBio.com
For media enquiries, please contact Imogen Quail, PR Manager,
imogen.quail@ramarketingpr.com, ramarketingpr.com
About Andelyn Biosciences, Inc.
Andelyn is a biopharmaceutical CDMO Pioneering Solutions That Turn Hope into
Reality™. Headquartered in the greater Columbus, Ohio, USA area, Andelyn’s
capabilities span viral vector process and analytical development, small to large
scale adherent and suspension based GMP drug substance manufacturing up to
2000L, and drug product manufacturing services. Having 20+ years of
experience in viral vector manufacturing, Andelyn offers its clients direct access
to globally recognized thought leaders that have enabled 75+ worldwide clinical
trials. With the experience gained from over 400 cGMP clinical batches and
2000+ research-grade productions, Andelyn provides its clients with end-to-end
manufacturing services, advanced quality systems, full regulatory support, and
supply chain vertical integration. Andelyn began operations in its state-of-the-art
200,000 sq. ft. commercial manufacturing facility in September 2022, expanding
capacity across 14+ production suites for customization of new programs and
tech transferred programs. Andelyn is one of a few select CDMOs that offer
clinical through commercial-scale capabilities that will help fulfil Andelyn’s
mission of accelerating the development and manufacturing of innovative
therapies to bring more treatments to more patients. Andelyn is owned and
supported by Nationwide Children’s Hospital (NCH) and Pall-Cytiva, part of
Danaher Corporation.
Full story
-
Oct 27, 2022, 01:00 AM
by
User Not Found
Bio-IT World | New consensus recommendations for using in silico approaches to validate next-generation sequencing data analysis pipelines; a pre-consortium collaboration for medical product development in alpha-1 antitrypsin deficiency; integrated drug discovery services to design, synthesize, and profile targeted heterobifunctional protein degraders; and more.
Full story
-
Oct 26, 2022, 10:04 AM
by
• Seven structures of 2D systems that had been experimentally analysed but not published (‘blind’) released to participants along with some experimental conditions.
• Boundaries pushed beyond the pharmaceutical sector to areas such as electronics and photonics with the inclusion of an optoelectronic system containing silicon and a metal-organic system containing copper.
• Also included one of the most challenging systems in CSP Blind Test history - a large, highly polymorphic, phamaceutical drug candidate.
• Test ran from October 2020 to September 2022.
• More experimental data released over the course of the test to simulate real world conditions.
• Submissions received from industrial and academic groups worldwide.
• All compounds successfully had their experimentally observed crystal structures predicted from landscapes of 1K+ potential structures.
• PXRD challenge showcased the application of CSP to industrially relevant molecules.
Full story
-
Oct 26, 2022, 10:03 AM
by
Inizio commits to SBTi Net-Zero Standard
Full story
-
Oct 26, 2022, 10:03 AM
by
Enterprise search provider Sinequa announced the appointment of Wendy Lurrie as its new Chief Marketing Officer. Sinequa works with some of the leading brands in pharma and life sciences including: Pfizer, GSK, Takeda, Astellas, AstraZeneca, UCB and others. As Sinequa’s new CMO, Wendy will help extend Sinequa’s global marketing and brand strategy for the important bio and life sciences sector, and support the company’s ongoing expansion of its North American presence.
Full story
-
Oct 26, 2022, 10:02 AM
by
Full story
-
Oct 26, 2022, 09:22 AM
by
User Not Found
Bio-IT World | At the American Society of Human Genetics meeting last night, Pacific Biosciences planned to host a “celebration of genomics.” Among the announcements, PacBio will give updates on its two new sequencing platforms: the Onso Sequencing System and the Revio long-read sequencing system, for which the company began taking orders last night.
Full story